Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

PHASE3CompletedINTERVENTIONAL
Enrollment

2,136

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Pneumonia
Interventions
DRUG

Tifacogin

Trial Locations (150)

2605

Garran

3011

Footscray

3050

Parkville

3084

Heidelburg

4215

Southport

6009

Nedlands

33744

Bay Pines

81545

München

Unknown

Mobile

Loma Linda

Los Angeles

Orange

Sacramento

San Diego

San Jose

Denver

Farmington

New Haven

Newark

Clearwater

Fort Lauderdale

Jacksonville

Atlanta

Conyers

Decatur

Chicago

Oak Park

Muncie

New Albany

Shreveport

Baltimore

Cumberland

Detroit

Southfield

St Louis

Butte

Reno

Buffalo

Johnson City

Greensboro

Winston-Salem

Cincinnati

Columbus

Toledo

Oklahoma City

Allentown

Pawtucket

Providence

Spartanburg

Knoxville

Dallas

San Antonio

Tyler

Salt Lake City

Norfolk

Winchester

Seattle

Tacoma

Mar del Plata

Tandil

Tres de Febrero

Capital Federal

Camperdown

Kingswood

Cairns

Nambour

Woodville

Hobart

Launceston

Box Hill

Perth

Brussels

Bouge

Braine-l'Alleud

Brussels

Ghent

Liège

Mons

Ottignies

Seraing

Yvoir

Fortaleza

Belgium, Salvador

Salvador

Curitiba

Recife

Pelotas

Porto Alegre

Florianópolis

Campinas

São José do Rio Preto

Calgary

Edmonton

New Westminster

Surrey

Vancouver

Victoria

Winnipeg

Hamilton

Kingston

Ottawa

Toronto

Greenfield Park

Montreal

Santiago

Temuco

Argenteuil

Belfort

Besançon

La Roche Sur Yoon

Limoges

Paris

Pierre-Bénite

Saint-Michel

Tours

Lübeck

Regensburg

George Town

Johor Bahru

Kota Bharu Kelantan

Kuala Lumpar

Kuala Selangor

's-Hertogenbosch

Rotterdam

Utrecht

Grafton

Otahuhu

Christchurch

Hastings

Lima

Singapore

KwaKhangela

Parktown

Bloemfontein

Centurion

Kimberley

Parktown West

Wŏnju

Namdong-gu

Gyeonggi-do

Gyunggi

Seoul

Suwon

Sabadell

Madrid

Palma de Mallorca

Santiago de Compostela

Glasgow

Livingston

London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY